Active Biotech Regains Rights Over Laquinimod from Teva Pharmaceutical
After Failing Phase III, Active Biotech is back to square one - Labiotech.eu
Teva and Active Biotech Expand Investigational MS Treatment Program
Teva Pharmaceuticals (@TevaUSA) / Twitter
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Active Biotech's partner Teva starts laquinimod clinical trial
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva: Leverage A Concern (NYSE:TEVA) | Seeking Alpha
Active Biotech: Latest News | Tracxn
Legato-HD Update | Huntington Society of Canada
Teva recalls US-made drugs following contamination fears - The Boston Globe
Teva and Active Biotech Announce CONCERTO trial of Laquinimod trial fails
Teva and Active Biotech Announce Concerto Trial of Laquinimod did not Meet Primary Endpoint | Pharmasources.com
Teva Pharmaceutical Industries Ltd - News, Articles etc. - European Pharmaceutical Review
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Teva Pharmaceuticals - Wikipedia
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
3 Reasons to Buy Teva Right Now - TheStreet
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv
PharmaShots | Incisive News in 3 Shots
